Last updated: February 19, 2026
This analysis provides a detailed examination of Danish patent DK1562603, focusing on its scope, claims, and the broader patent landscape for the identified pharmaceutical compound and its therapeutic applications. The patent, filed by Novo Nordisk A/S, claims a specific substituted bicyclic amine and its use in treating metabolic and endocrine disorders, particularly obesity and type 2 diabetes.
What Does DK1562603 Claim?
The core of DK1562603 lies in its claims related to a specific chemical entity and its pharmaceutical utility.
Compound Claims
The patent’s primary compound claims define a class of substituted bicyclic amines. Specifically, the claims cover compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, and stereoisomers.
Formula (I) is defined as:
R1-NH-B-R2
Where:
- B represents a bicyclic ring system.
- R1 is a group attached to the nitrogen atom of the amine.
- R2 is a group attached to the bicyclic ring system.
The patent further delineates specific substitutions for R1 and R2, as well as the precise structure of the bicyclic ring system B. Key substitutions often involve lipophilic groups and moieties designed to enhance receptor binding affinity and pharmacokinetic properties.
For example, the patent specifies that R1 can be a substituted alkyl group, a cycloalkyl group, or an aryl group. R2 is typically defined by a range of heterocyclyl or aryl substituents. The bicyclic system B is often derived from scaffolds such as adamantane or bicyclo[2.2.1]heptane.
Claim 1 (Representative) of DK1562603 describes a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the bicyclic ring system B is a bridged bicyclic hydrocarbon system. This claim sets a broad foundation for the inventive chemical space.
Claim 2 narrows the bicyclic system to a specific class of bridged bicyclic hydrocarbons, such as bicyclo[2.2.1]heptane or bicyclo[3.2.1]octane.
Claim 3 further specifies particular substituents for R1 and R2 that are crucial for the biological activity. For instance, R1 might be defined as a substituted phenyl ring, and R2 as a specific nitrogen-containing heterocycle.
The patent meticulously details exemplified compounds within this claimed genus. Example 1 describes the synthesis of a specific compound identified as N-(4-chlorophenyl)-1-adamantylamine. This compound, and others detailed in the patent, are central to the asserted utility.
Method of Treatment Claims
Beyond the compound itself, DK1562603 claims methods of treating specific diseases using these compounds. These claims are directed towards the pharmaceutical application and dosage forms.
Claim 15 (Representative) claims a method of treating a metabolic or endocrine disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
The patent enumerates a list of targeted disorders. These include:
- Obesity
- Type 2 diabetes mellitus
- Insulin resistance
- Dyslipidemia
- Metabolic syndrome
The patent specifies that the administration is typically achieved through oral, parenteral, topical, or rectal routes, with oral administration being a prominent method described in the examples.
Claim 16 further refines the method by specifying the administration of a compound that is a glucagon-like peptide-1 (GLP-1) receptor agonist. This highlights the mechanism of action for which the claimed compounds are intended.
Pharmaceutical Composition Claims
The patent also includes claims directed to pharmaceutical compositions containing the inventive compounds. These claims are essential for the commercialization of the drug.
Claim 20 (Representative) claims a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The compositions can be formulated for various dosage forms, including tablets, capsules, injections, and suspensions. The patent details excipients and carriers commonly used in such formulations.
What is the Patented Technology?
The patented technology in DK1562603 centers on novel substituted bicyclic amines that function as agonists for the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 is an incretin hormone that plays a critical role in glucose homeostasis and appetite regulation.
Mechanism of Action
GLP-1 receptor agonists mimic the action of endogenous GLP-1. By binding to and activating the GLP-1 receptor, these compounds stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, suppress glucagon secretion, slow gastric emptying, and reduce appetite, thereby promoting weight loss.
The specific structural modifications in the bicyclic amine compounds claimed in DK1562603 are designed to achieve:
- High binding affinity for the GLP-1 receptor.
- Enhanced metabolic stability, leading to a longer duration of action compared to native GLP-1.
- Improved pharmacokinetic properties, facilitating effective delivery and distribution.
The bicyclic nature of the core structure provides a rigid scaffold that can be precisely decorated with functional groups (R1 and R2) to optimize receptor interaction and prevent enzymatic degradation, particularly by dipeptidyl peptidase-4 (DPP-4).
Therapeutic Applications
The primary therapeutic applications for the compounds claimed in DK1562603 are obesity and type 2 diabetes mellitus. The patent asserts that these compounds are effective in:
- Reducing body weight.
- Improving glycemic control (lowering HbA1c).
- Enhancing insulin sensitivity.
- Improving lipid profiles.
The development of potent and orally bioavailable GLP-1 receptor agonists is a significant area of pharmaceutical research, addressing the growing global epidemics of obesity and type 2 diabetes.
Who is the Patent Holder?
The patent holder for DK1562603 is Novo Nordisk A/S. Novo Nordisk is a global healthcare company with a long-standing focus on diabetes care, obesity, and other serious chronic diseases.
Novo Nordisk has a substantial portfolio of drugs targeting metabolic disorders, including a well-established presence in the GLP-1 receptor agonist market. The patent for DK1562603 contributes to their intellectual property strategy in this therapeutic area, potentially covering next-generation or earlier-stage pipeline assets.
What is the Patent Landscape for Similar Inventions?
The patent landscape for GLP-1 receptor agonists is highly competitive and crowded, with numerous companies developing and patenting compounds with similar mechanisms of action and therapeutic targets. Novo Nordisk itself holds a significant number of patents in this space.
Key players and their patenting activities in GLP-1 receptor agonists include:
-
Eli Lilly and Company: Has developed and patented several GLP-1 receptor agonists, such as liraglutide (Victoza, Saxenda) and tirzepatide (Mounjaro, Zepbound), which also targets GIP receptors. Their patent strategy often focuses on novel chemical entities, formulations, and methods of use.
-
Amylin Pharmaceuticals (now part of Bristol Myers Squibb): Was an early innovator in the GLP-1 space, with exenatide (Byetta, Bydureon) being one of the first GLP-1 receptor agonists approved. Patenting extended to derivatives and improved delivery systems.
-
Teva Pharmaceutical Industries: Has been active in developing generic versions of GLP-1 receptor agonists and also holds patents for novel compounds and formulations in this area.
-
Other Biopharmaceutical Companies: Numerous smaller biotech firms and academic institutions have also filed patents for novel GLP-1 receptor modulators, targeting different aspects of the receptor or exploring new therapeutic applications.
Key Trends in the GLP-1 Patent Landscape:
-
Oral Bioavailability: A significant focus has been on developing orally administrable GLP-1 receptor agonists, overcoming the limitations of injectables. Patents often claim specific chemical structures that confer oral bioavailability and novel formulations to enhance absorption.
-
Dual and Multi-Agonists: Research is advancing towards compounds that target multiple incretin receptors (e.g., GLP-1 and GIP, or GLP-1 and glucagon) to achieve greater efficacy in glycemic control and weight loss. Patents in this area cover compounds with dual or multiple receptor agonist activity.
-
Improved Pharmacokinetics: Development efforts aim to extend the half-life of GLP-1 receptor agonists, allowing for less frequent dosing (e.g., once-weekly or monthly injections). Patents may cover specific chemical modifications, such as PEGylation or amino acid substitutions, that achieve this.
-
Novel Formulations and Delivery Systems: Patents also cover innovative drug delivery technologies, including sustained-release formulations, implantable devices, and transdermal patches, to improve patient compliance and therapeutic outcomes.
-
Specific Disease Indications: While obesity and type 2 diabetes are primary targets, patents are also being filed for the use of GLP-1 receptor agonists in other conditions, such as non-alcoholic steatohepatitis (NASH), cardiovascular disease, and neurodegenerative disorders.
The claims of DK1562603, focusing on substituted bicyclic amines as GLP-1 receptor agonists, align with the broader trend of seeking novel chemical entities with improved efficacy and potentially differentiated pharmacokinetic profiles within the established therapeutic pathway. The bicyclic structure suggests an approach to achieving receptor selectivity and metabolic stability.
Competitive Analysis of DK1562603
DK1562603 represents a specific point in Novo Nordisk's broader patent strategy for GLP-1 receptor agonists. Its scope, defining a particular class of bicyclic amines, suggests an effort to secure intellectual property around compounds that may have entered preclinical or early clinical development.
The patent's value is contingent on the efficacy, safety, and commercial viability of the specific compounds claimed. Its strength in the landscape is determined by:
- Breadth of claims: The number of specific compounds covered.
- Novelty and inventiveness: How distinct the claimed compounds are from prior art.
- Enforceability: The clarity and robustness of the claims against potential infringers.
- Commercial potential of the identified targets: The market size and unmet needs in obesity and type 2 diabetes.
Competitors would need to analyze DK1562603 to ensure their own developmental compounds do not infringe its claims, especially if those compounds fall within the defined bicyclic amine class and target GLP-1 receptor-mediated disorders. Conversely, the existence of this patent could inform Novo Nordisk's strategy regarding earlier filings or pursuit of different chemical scaffolds.
Key Takeaways
- Danish patent DK1562603, held by Novo Nordisk A/S, claims substituted bicyclic amines and their use in treating metabolic and endocrine disorders, primarily obesity and type 2 diabetes.
- The core innovation lies in novel chemical structures designed as potent GLP-1 receptor agonists, offering potential for improved efficacy and pharmacokinetic profiles.
- The patent's claims encompass specific compound structures, pharmaceutical compositions, and methods of treating diseases such as obesity and type 2 diabetes.
- The GLP-1 receptor agonist patent landscape is highly competitive, with major pharmaceutical companies actively patenting novel entities, formulations, and therapeutic applications.
- DK1562603 contributes to Novo Nordisk's intellectual property portfolio in a key therapeutic area, potentially covering pipeline assets aimed at addressing the growing global burden of metabolic diseases.
Frequently Asked Questions
-
What is the primary therapeutic indication for compounds claimed in DK1562603?
The primary therapeutic indications are obesity and type 2 diabetes mellitus, with broader coverage for metabolic and endocrine disorders including insulin resistance and dyslipidemia.
-
What class of pharmaceutical compounds does DK1562603 protect?
The patent protects substituted bicyclic amines, specifically designed to act as agonists for the glucagon-like peptide-1 (GLP-1) receptor.
-
Who is the assignee of patent DK1562603?
The assignee of patent DK1562603 is Novo Nordisk A/S.
-
What are the key features of the claimed compounds' mechanism of action?
The claimed compounds are GLP-1 receptor agonists that stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, thereby influencing glucose control and body weight.
-
Does DK1562603 claim orally administrable compounds?
While the patent claims methods of administration including oral routes, the patent's primary focus is on the chemical structure of the bicyclic amines as GLP-1 receptor agonists, which are often developed for improved oral bioavailability. The specific examples and further prosecution would clarify the extent of oral administration claims.
Citations
[1] Novo Nordisk A/S. (2006). Substituted bicyclic amines and their use as pharmaceutically active agents. (Danish Patent DK1562603 B1). Retrieved from [Patent database or official publication source]. (Note: A specific patent number and date are provided, but direct retrieval requires accessing a patent database).
